Ianalumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | BAFF receptor |
| Clinical data | |
| Other names | VAY736 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ianalumab (
This drug is being developed by
III trials.[5][6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.[7]
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ^ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.
- PMID 32067925.
- S2CID 222150641.
- ^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
- ^ "Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab". Pharmaceutical Technology. 30 June 2023.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |